332 related articles for article (PubMed ID: 35295612)
21. Predictive 'biomarker piggybacking': an examination of reflexive pan-cancer screening with pan-TRK immunohistochemistry.
Sholl LM; Zheng M; Nardi V; Hornick JL
Histopathology; 2021 Aug; 79(2):260-264. PubMed ID: 33682174
[TBL] [Abstract][Full Text] [Related]
22. Pan-TRK Immunohistochemistry Is Highly Correlated With NTRK3 Gene Rearrangements in Salivary Gland Tumors.
Csanyi-Bastien M; Lanic MD; Beaussire L; Ferric S; François A; Meseure D; Jardin F; Wassef M; Ruminy P; Laé M
Am J Surg Pathol; 2021 Nov; 45(11):1487-1498. PubMed ID: 33899788
[TBL] [Abstract][Full Text] [Related]
23. NTRK gene fusion testing and management in lung cancer.
Repetto M; Chiara Garassino M; Loong HH; Lopez-Rios F; Mok T; Peters S; Planchard D; Popat S; Rudzinski ER; Drilon A; Zhou C
Cancer Treat Rev; 2024 Jun; 127():102733. PubMed ID: 38733648
[TBL] [Abstract][Full Text] [Related]
24. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls.
Solomon JP; Linkov I; Rosado A; Mullaney K; Rosen EY; Frosina D; Jungbluth AA; Zehir A; Benayed R; Drilon A; Hyman DM; Ladanyi M; Sireci AN; Hechtman JF
Mod Pathol; 2020 Jan; 33(1):38-46. PubMed ID: 31375766
[TBL] [Abstract][Full Text] [Related]
25. Neurotrophic tyrosine receptor kinase fusion in pediatric central nervous system tumors.
Lang SS; Kumar NK; Madsen P; Gajjar AA; Gajjar E; Resnick AC; Storm PB
Cancer Genet; 2022 Apr; 262-263():64-70. PubMed ID: 35108662
[TBL] [Abstract][Full Text] [Related]
26. NTRK Fusions Detection in Paediatric Sarcomas to Expand the Morphological Spectrum and Clinical Relevance of Selected Entities.
Nozzoli F; Lazar AJ; Castiglione F; Campanacci DA; Beltrami G; De Logu F; Caporalini C; Massi D; Roviello G
Pathol Oncol Res; 2022; 28():1610237. PubMed ID: 35295613
[TBL] [Abstract][Full Text] [Related]
27. NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma.
Chiang S; Cotzia P; Hyman DM; Drilon A; Tap WD; Zhang L; Hechtman JF; Frosina D; Jungbluth AA; Murali R; Park KJ; Soslow RA; Oliva E; Iafrate AJ; Benayed R; Ladanyi M; Antonescu CR
Am J Surg Pathol; 2018 Jun; 42(6):791-798. PubMed ID: 29553955
[TBL] [Abstract][Full Text] [Related]
28. Identifying patients with NTRK fusion cancer.
Solomon JP; Benayed R; Hechtman JF; Ladanyi M
Ann Oncol; 2019 Nov; 30(Suppl_8):viii16-viii22. PubMed ID: 31738428
[TBL] [Abstract][Full Text] [Related]
29. Testing algorithm for identification of patients with TRK fusion cancer.
Penault-Llorca F; Rudzinski ER; Sepulveda AR
J Clin Pathol; 2019 Jul; 72(7):460-467. PubMed ID: 31072837
[TBL] [Abstract][Full Text] [Related]
30. Detection of NTRK1/3 Rearrangements in Papillary Thyroid Carcinoma Using Immunohistochemistry, Fluorescent In Situ Hybridization, and Next-Generation Sequencing.
Lee YC; Chen JY; Huang CJ; Chen HS; Yang AH; Hang JF
Endocr Pathol; 2020 Dec; 31(4):348-358. PubMed ID: 32880785
[TBL] [Abstract][Full Text] [Related]
31. MLH1/PMS2 Expression Could Tell Classical NTRK Fusion in Fluorescence
Fu Y; Li Z; Gao F; Yang J; Wu H; Zhang B; Pu X; Fan X
Front Oncol; 2021; 11():669197. PubMed ID: 33996597
[TBL] [Abstract][Full Text] [Related]
32. Interlaboratory Comparison Study (Ring Test) of Next-Generation Sequencing-Based NTRK Fusion Detection in South Korea.
Lee SE; Lee MS; Jeon YK; Shim HS; Kang J; Kim J; Choi YL
Cancer Res Treat; 2023 Jan; 55(1):28-40. PubMed ID: 35167738
[TBL] [Abstract][Full Text] [Related]
33. Detection of
Solomon JP; Hechtman JF
Cancer Res; 2019 Jul; 79(13):3163-3168. PubMed ID: 31196931
[TBL] [Abstract][Full Text] [Related]
34. Limited Accuracy of Pan-Trk Immunohistochemistry Screening for
Macerola E; Proietti A; Poma AM; Vignali P; Sparavelli R; Ginori A; Basolo A; Elisei R; Santini F; Basolo F
Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806472
[TBL] [Abstract][Full Text] [Related]
35. Molecular characterization of cancers with NTRK gene fusions.
Gatalica Z; Xiu J; Swensen J; Vranic S
Mod Pathol; 2019 Jan; 32(1):147-153. PubMed ID: 30171197
[TBL] [Abstract][Full Text] [Related]
36. NTRK fusion analysis reveals enrichment in Middle Eastern BRAF wild-type PTC.
Kong Y; Bu R; Parvathareddy SK; Siraj AK; Siraj N; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
Eur J Endocrinol; 2021 Apr; 184(4):503-511. PubMed ID: 33524004
[TBL] [Abstract][Full Text] [Related]
37. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.
Marchiò C; Scaltriti M; Ladanyi M; Iafrate AJ; Bibeau F; Dietel M; Hechtman JF; Troiani T; López-Rios F; Douillard JY; Andrè F; Reis-Filho JS
Ann Oncol; 2019 Sep; 30(9):1417-1427. PubMed ID: 31268127
[TBL] [Abstract][Full Text] [Related]
38. NTRK fusions are extremely rare in bone tumours.
Lam SW; Briaire-de Bruijn IH; van Wezel T; Cleven AHG; Hogendoorn PCW; Cleton-Jansen AM; Bovée JVMG
Histopathology; 2021 Nov; 79(5):880-885. PubMed ID: 34148257
[TBL] [Abstract][Full Text] [Related]
39. Pan-TRK immunohistochemistry as screening tool for NTRK fusions: A diagnostic workflow for the identification of positive patients in clinical practice.
Vingiani A; Lorenzini D; Conca E; Volpi CC; Trupia DV; Gloghini A; Perrone F; Tamborini E; Dagrada GP; Agnelli L; Capone I; Busico A; Pruneri G
Cancer Biomark; 2023; 38(3):301-309. PubMed ID: 37545217
[TBL] [Abstract][Full Text] [Related]
40. Identifying patients with NTRK fusion cancer.
Solomon JP; Benayed R; Hechtman JF; Ladanyi M
Ann Oncol; 2019 Nov; 30 Suppl 8():viii16-viii22. PubMed ID: 32223934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
